PALO ALTO, Calif., Jan. 3 /PRNewswire/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) and Incyte Pharmaceuticals, Inc. (Nasdaq: INCY) announced that the American Heart Association has selected CV Therapeutics' discovery of the role of the "good" cholesterol-regulating gene, ABC1, as one of the top ten 1999 research advances in heart disease and stroke. This discovery was presented at the American Heart Association's 72nd Scientific Sessions and published in the Journal of Clinical Investigation in 1999. Through the use of Incyte's gene expression microarray technology along with other techniques, scientists at CV Therapeutics, working with Incyte and University of Washington, identified that ABC1 is a key gene involved in the formation of high density lipoprotein (HDL), or "good" cholesterol. Richard M. Lawn, Ph.D., Vice President, Discovery Research at CV Therapeutics and his colleagues at CVT then demonstrated that increasing levels of this gene in cultured cells in the laboratory enhances the removal of cholesterol from cultured cells. These discoveries provided the first biological evidence suggesting that drug therapies that increase the level of ABC1 might aid in the removal of cholesterol from the body, holding the potential for reducing the risk of heart disease among the general population. According to the American Heart Association, the annual list was first created in 1996 to highlight the achievements in basic and clinical research that may have the greatest impact in improving the prevention and treatment of cardiovascular disease, the nation's number one killer. "The American Heart Association's recognition is testimony to the potential this finding holds for discovering new therapeutic solutions for HDL cholesterol management," said Louis G. Lange, M.D., Ph.D., Chairman and Chief Executive Officer of CV Therapeutics. "This discovery demonstrates how combining cardiovascular expertise along with the power of genomics and microarray technology can lead to new drug discovery targets that could potentially help the many people suffering from cardiovascular diseases." This discovery also represented the first time gene expression microarray analysis has been used to identify a defect associated with a human genetic condition. This technique uses a micro-chip with thousands of genes covering its surface. Microarray analysis dramatically reduces the amount of time usually necessary to monitor the expression level of thousands of genes concurrently. Scientists were able to pinpoint the faulty gene and its encoded protein with the help of Incyte's Gene Album(TM) microarrays by studying the activity of 60,000 genes from people with Tangier disease, a rare genetic disorder that results in dangerously low levels of HDL, and an increased risk for heart attack, against genes from an unaffected individual. "This is a validation of the role of genomics in the understanding and treatment of disease," said Randy Scott, President and Chief Scientific Officer of Incyte Pharmaceuticals. "We are appreciative of the acknowledgement by the American Heart Association and would welcome future collaboration opportunities with CV Therapeutics." The CV Therapeutics and Incyte collaboration is focused on creating gene expression profiles of cardiovascular disease models. CV Therapeutics contributes its molecular cardiology expertise and Incyte contributes its genomics expertise to the collaboration. In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, uncertainties related to CV Therapeutics' early stage of development and clinical trials. Actual results could differ materially. Factors that could cause or contribute to such differences are more fully discussed in CV Therapeutics' Prospectus dated October 6, 1999. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Annual Report on Form 10-Q for the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has three drug candidates in clinical trials. Ranolazine, the first in a new class of drugs known as partial fatty acid oxidation (pFOX) inhibitors for the potential treatment of angina, is in Phase III clinical trials. CVT-510, for the potential treatment of atrial arrhythmias, is in Phase II clinical trials. A third product, CVT-124, for the potential treatment of congestive heart failure (CHF), is in Phase II clinical trials. For more information, please visit CV Therapeutics' web site at www.cvt.com. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at www.incyte.com
SOURCE CV Therapeutics, Inc.; Incyte Pharmaceuticals, Inc.